MX2024010900A - Metodos para tratar el cancer de pulmon de celulas peque?as. - Google Patents

Metodos para tratar el cancer de pulmon de celulas peque?as.

Info

Publication number
MX2024010900A
MX2024010900A MX2024010900A MX2024010900A MX2024010900A MX 2024010900 A MX2024010900 A MX 2024010900A MX 2024010900 A MX2024010900 A MX 2024010900A MX 2024010900 A MX2024010900 A MX 2024010900A MX 2024010900 A MX2024010900 A MX 2024010900A
Authority
MX
Mexico
Prior art keywords
methods
lung cancer
small cell
cell lung
treating small
Prior art date
Application number
MX2024010900A
Other languages
English (en)
Spanish (es)
Inventor
Lars Damstrup
Claudio Zanna
Imedio Esteban Rodrigo
Luke Piggott
Anne Bellon
Valerie Nicolas
Chessex Anne Vaslin
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2024010900A publication Critical patent/MX2024010900A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024010900A 2022-03-07 2023-03-07 Metodos para tratar el cancer de pulmon de celulas peque?as. MX2024010900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
PCT/EP2023/055751 WO2023170065A1 (en) 2022-03-07 2023-03-07 Methods of treating small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2024010900A true MX2024010900A (es) 2024-09-17

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010900A MX2024010900A (es) 2022-03-07 2023-03-07 Metodos para tratar el cancer de pulmon de celulas peque?as.

Country Status (12)

Country Link
US (1) US20260027117A1 (https=)
EP (1) EP4489756A1 (https=)
JP (1) JP2025509278A (https=)
KR (1) KR20240158972A (https=)
CN (1) CN118843466A (https=)
AR (1) AR128711A1 (https=)
AU (1) AU2023232376A1 (https=)
CA (1) CA3253688A1 (https=)
IL (1) IL315441A (https=)
MX (1) MX2024010900A (https=)
TW (1) TW202337469A (https=)
WO (1) WO2023170065A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5129812B2 (ja) 2007-06-15 2013-01-30 Ｍｓｄ株式会社 ビシクロアニリン誘導体
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
CN117794932A (zh) 2021-06-04 2024-03-29 阿普里治疗股份有限公司 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
EP4489756A1 (en) 2025-01-15
CN118843466A (zh) 2024-10-25
KR20240158972A (ko) 2024-11-05
WO2023170065A1 (en) 2023-09-14
AU2023232376A1 (en) 2024-10-10
IL315441A (en) 2024-11-01
JP2025509278A (ja) 2025-04-11
TW202337469A (zh) 2023-10-01
US20260027117A1 (en) 2026-01-29
AR128711A1 (es) 2024-06-05
CA3253688A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MX2025001648A (es) Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras)
MX2025015502A (es) Inhibidores del oncogén de sarcoma de rata de kirsten (kras)
MX2024010900A (es) Metodos para tratar el cancer de pulmon de celulas peque?as.
MX2023008193A (es) Procedimientos para tratar el cáncer.
WO2021247543A3 (en) Nucleic acid library methods
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
PH12021552805A1 (en) Cdk inhibitors
MX2024000230A (es) Inhibidores de cdk2.
ZA202402178B (en) 3clpro protease inhibitor
WO2023096977A3 (en) Modified prime editing guide rnas
WO2022043754A3 (en) Radiopharmaceutical and methods
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
MX2025012153A (es) Inhibidores de cdk2
AU2023409223A1 (en) Cancer treatments using mta-cooperative prmt5 inhibitors
AU2022299158A1 (en) Wee1 inhibitors and methods for treating cancer
MX2024014450A (es) Composiciones de genoterapia y metodos de uso de las mismas
CA227550S (en) Lock escutcheon
EP4691564A3 (en) Neurokinin inhibitors such as aprepitant for treating non small cell lung carcinoma or breast cancer without mutations
MX2024001899A (es) Moduladores del canal de potasio.
CA227224S (en) Inhaler
MX2024011347A (es) Inhibidor de la interaccion proteina-proteina mll1-wdr5 haloalquilpiridiltriazol
CR20240494A (es) Composiciones y métodos para inhibir la expresión de snca
WO2024059757A3 (en) Methods for reprograming exhausted t cells and boosting immune checkpoint blockade therapy for cancer
WO2024220666A3 (en) Treatment of non-small cell lung cancer
AU2022903198A0 (en) Methods for treating small cell lung cancer